SMI Equal Weight

SMI Equal Weight handeln
378,16 PKT -2,78 PKT -0,73 %
finanzen.net zero
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

ISIN CH1528602787


Analysen zu SMI Equal Weight-Werten

Datum Rating Analyst
12.06.12 UBS neutral UBS AG
12.06.12 UBS sell Société Générale Group S.A. (SG)
12.06.12 Swiss Life buy Nomura
12.06.12 UBS hold Société Générale Group S.A. (SG)
11.06.12 Nestlé hold Société Générale Group S.A. (SG)
11.06.12 UBS hold Commerzbank Corp. & Markets
11.06.12 Novartis hold Vontobel Research
08.06.12 Novartis neutral J.P. Morgan Cazenove
08.06.12 ABB (Asea Brown Boveri) buy Citigroup Corp.
08.06.12 UBS buy WestLB AG
08.06.12 Logitech neutral Sarasin Research
08.06.12 Logitech hold Vontobel Research
06.06.12 Holcim neutral Goldman Sachs Group Inc.
06.06.12 Holcim sell Goldman Sachs Group Inc.
06.06.12 Geberit hold Vontobel Research
05.06.12 Novartis hold Vontobel Research
04.06.12 Novartis neutral Exane-BNP Paribas SA
04.06.12 Swiss Re neutral Exane-BNP Paribas SA
04.06.12 Novartis neutral Citigroup Corp.
04.06.12 Novartis hold Vontobel Research
04.06.12 Zurich Insurance buy Vontobel Research
01.06.12 Swiss Re buy UBS AG
01.06.12 Swiss Re hold Société Générale Group S.A. (SG)
01.06.12 Kühne + Nagel International underperform Cheuvreux SA
01.06.12 Lonza hold Vontobel Research
31.05.12 Swiss Re overweight J.P. Morgan Cazenove
31.05.12 ABB (Asea Brown Boveri) neutral Exane-BNP Paribas SA
31.05.12 Swiss Re buy Sarasin Research
31.05.12 Swiss Re add Commerzbank Corp. & Markets
31.05.12 Holcim overweight Morgan Stanley
31.05.12 Holcim equal-weight Morgan Stanley
31.05.12 Swiss Life hold Société Générale Group S.A. (SG)
31.05.12 Swiss Re buy Vontobel Research
31.05.12 Novartis buy Deutsche Bank AG
30.05.12 Novartis outperform Credit Suisse Group
30.05.12 Holcim outperform Exane-BNP Paribas SA
29.05.12 Novartis neutral J.P. Morgan Cazenove
29.05.12 Novartis buy UBS AG
29.05.12 Novartis buy UBS AG
29.05.12 UBS neutral Sarasin Research